Current News

The InnovationTriologie have recently completed a hybrid training program—combining web-based and face-to-face learning—on the current ICH-GCP E6(R3) guideline at Staburo GmbH in Munich. This comprehensive initiative has successfully trained more than 80 participants, equipping them with the essential knowledge and practical insights to implement the new Good Clinical Practice (GCP) guideline in the daily routines. Link: Staburo At ICH E6 (R3) Training  | Data science, biostatistics, data transparency, bioinformatics and statistical programming

The feedback has been very positive:
Participants engaged deeply with the material, appreciated the interactive format, and highlighted the relevance of the content to their day-to-day work in clinical research. We, at InnovationTriologie, are highly motivated by the positive feedback and are already looking forward to offering the next round of training.

Get Ready for July 2025

As a reminder, the new ICH-GCP E6(R3) guideline will become mandatory in the EU starting 23 July 2025. This shift brings important updates in quality- and risk management, data governance, and trial oversight—making preparation not just beneficial but essential.

InnovationTriologie is here to support organizations and professionals in understanding and applying these new standards. Whether you're an individual seeking to stay ahead or a company aiming to upskill your teams—we're ready to help you make the transition confidently.

📩 Reach out to us to learn more about our ACTA Education training options at training(at)triologie.org

With the release of the new ICH/GCP guideline ICH E6(R3) on 06-Jan-2025, continuous risk management in clinical trials has moved further into the spotlight. In this context, the use of Artificial Intelligence (AI) opens up new opportunities to meet the growing regulatory demands.

Helge Bonaventura and Dr. Andreas Berk described practical AI use cases that can enhance efficiency and mitigate risks in clinical research in a paper, that was published in the PM/QM journal by DGPharMed and German Quality Management Association e.V. In the article “Application of Artificial Intelligence in Risk Management of Clinical Trials” both aspects are addressed, the potential and the challenges of these technologies within the regulatory framework of ICH E6(R3).

The content of this article, which was also presented at the annual congress of DGPharMed 2025, reflects our ongoing commitment to innovation in clinical research and our efforts to improve the quality and safety of clinical trials by using AI tools and methods.

Download the full article as a PDF here: t3://file?uid=136

In the latest issue of pharmind (3/2025), Dr. Andreas Berk and Dr. Matthias Klüglich explore the growing role of Artificial Intelligence (AI) in Clinical Development. The article highlights current applications such as AI-assisted report generation, optimization of inclusion criteria, and automated quality control processes.

Both authors provide a balanced perspective, acknowledging the transformative potential of AI while emphasizing the importance of critically assessing its limitations and ethical implications. As the technology evolves rapidly, Dr. Matthias Klüglich and Dr. Andreas Berk call for ongoing evaluation to ensure responsible and effective integration into Clinical Research.

The role of Artificial Intelligence in Clinical Development was the central focus of a prestigious event held at the German Museum of Technology in Berlin. Initiated and supported by EventTriologie, the event brought together leading experts from Pharma and Industry to generate innovative impulses in Clinical Development. 

Instead of admission fees, donations were collected. A donation check of EUR 5,000 was presented to the Sonnenhof Children's Hospice in Berlin. The management and employees of BusinessTriologie were not just guests at this event – part of the donation was made possible by the entire BusinessTriologie team.

InnovationTriologie is proud to take responsibility for a comprehensive training concept. In today's clinical development environment, knowledge management has become an increasingly important factor. We are pleased to be able to provide a meaningful support to our customer.

Participants from InnovationTriologie attended the EUCROF25 congress in Copenhagen. The congress was meticulously designed to address the multifaceted nature of clinical research, covering essential topics such as regulatory changes, clinical trial technologies, quality assurance, data management and patient-centric approaches. The exchange with counterparts at European level was very helpful and provided new impulses.

In its 14th year, the Triologie Group continues to prioritize customer satisfaction as its core value. Our collaboration thrives on a commitment to excellence and a shared passion for achieving mutual project goals,

all within the complex framework of cost constraints and regulatory requirements in drug development. The trust shown by repeat business in 2025 serves as a powerful motivator for our entire team.

We extend our warmest wishes for a Merry Christmas and a prosperous New Year, filled with joy, good health, and abundant opportunities. Reflecting on 2024, we take great pride in the successful realization of our project targets, the implementation of ACTA, and the organizational changes we have achieved. 

Looking ahead, we are filled with anticipation and motivation for the exciting journey in 2025.

In 2025, we will embrace the theme of "STAYING TOGETHER," our vision aligned with the strategic decisions made by our leadership.

An advanced workshop was conducted on 11 December 2024 in Germany, aimed at providing an in-depth understanding of recent regulatory changes within the field of pharmaceutical development. 

The workshop, attended by over 100 employees from a Top 20 pharmaceutical company, integrated practical examples to illustrate the evolving regulatory environment. Feedback from participants was very positive, highlighting a strong sense of engagement and appreciation for the ACTA team’s efforts.

Participants from InnovationTriologie attended the BVMA Congress in Munich, which provided critical insights into the evolving regulatory landscape and emerging trends within the pharmaceutical and biotech sectors. This gathering proved invaluable in understanding the dynamic regulatory environment and implications for the industry.

An innovative Expert Meeting on Sustainability, organized by EventTriologie, was held in Stuttgart, gathering thought leaders from pharma, biotech, the arts, and science sectors, including Olympic medalists.

The discussions centered on future sustainability strategies, with an emphasis on cross-sector collaborations and disruptive innovations that could catalyze transformative change in the years to come. All attendees expressed their dedication to developing long-term, impactful strategies both professionally and personally.

The Thuringian Cancer Run is part of the prevention project ‘You are valuable - cancer prevention through mobility’, which aims to motivate all Thuringians to exercise more, independently of age, gender and fitness.

As part of this initiative, an outdoor event was held in Apolda on 25 October 2024. The registration fee of EUR 20.00 per participant will be used for various cancer prevention projects of the Thuringian Cancer Society. Axel Janke from BusinessTriologie completed a 7,5 km run for a good cause and thus supported this initiative. Many thanks, Axel.

On 16 and 17 October 2024, our IT team attended the prestigious Cybersecurity Conference held in Mannheim. The event provided deep insights into the latest developments in IT security, including emerging standards like the NIS-2 Directive and the Cyber Resilience Act, which are set to play a crucial role in European security frameworks.

In addition to informative presentations and discussions, our team took advantage of networking opportunities, exchanging ideas with other experts on innovative approaches to enhancing cybersecurity. New partnerships were established, which will support our company in future projects.

A key focus of the conference was the role of Artificial Intelligence (AI) in cybersecurity. AI is increasingly being used as a powerful tool to defend against cyberattacks, but it also poses risks, as criminals are leveraging AI to intensify their attacks. Companies must stay vigilant and continuously adapt their security strategies to prepare for these new threats.

Our IT team returns with fresh ideas and insights, ready to implement these new learnings to further strengthen our company’s security.

Achieving success once may be attributed to luck, but repeating it demonstrates unwavering dedication, strategic effort and a commitment to integrity and reliability—qualities that are indispensable in today's business landscape. This accomplishment would not have been possible without the collective expertise and innovation of our team. The Management would like to extend its sincere appreciation to all employees, whose contributions are vital to our continued success.

Our deepest gratitude goes to our business partners for their trust and collaboration. Your confidence in us has been instrumental in driving our shared achievements. As we look to the future, Triologie is ready to embrace the next way of growth and success together.

Effective July 1st, the executive team of BusinessTriologie expands as the new Chief Operating Officer assumes his position, enhancing our leadership. We warmly welcome Robert Kindervater and wish him great success in his new position.

Effective July 1st, the executive team of InnovationTriologie expands as the new Chief Operating Officer assumes his position, enhancing our leadership. We warmly welcome Dr. Andreas Berk and wish him great success in his new position.

We were represented at this year's DGPharMed congress on April 18^th and 19^th, 2024, in Mainz with two of our own exhibition stands. Detailed explanations and insights into our wide range of services, successful consultations, and information about our training academy ACTA were eagerly sought after. We are very pleased with the numerous interested parties and positive feedback that we were able to record.

On March 21^st, 2024  an expert discussion by InnovationTriologie on the topic “AI in drug development” took place in Berlin. Three engaging keynote speeches shed light on the development and application possibilities of artificial intelligence from various perspectives. This was followed by a discussion round that promoted interdisciplinary exchange. The event provided valuable insights and highlighted the importance of this topic for science, business, and society. 

Supporting the Sonnenhof children's hospice in Berlin (Björn Schulz Stiftung (bjoern-schulz-stiftung.de) is a personal endeavor for all of us. Our donation helps to improving the lives of children with life-limiting illnesses and to support their families in difficult circumstances.

In the 12^th year of the Triologie Group's existence, customer satisfaction is still our top priority. This cooperation is characterized by commitment and pleasure in achieving common project goals under the cost constraints and regulatory density in drug development. New projects in the areas of quality management, project coaching and knowledge management for our customers are both a motivation and an incentive.

Sustainability is an extremely important topic and a central concern of the entire Triologie Group. A large number of measures were already put in place 12 years ago. From the decision in favor of an environmentally focused home office model to the e-mobility strategy, the "Team in Orange" is assuming social responsibility.

We wish all our business partners and their loved ones a joyful and prosperous New Year. Best wishes for 2024. Thank you for trusting us.